ESR1 and neoplasm: While an AI reduces systemic estrogen levels by inhibiting aromatase, the enzyme that converts androgens into estrogens, fulvestrant (SERD) binds to and degrades estrogen receptors (ERs), blocking estrogen signaling and reducing ER-driven tumor growth and potentially prevents ER reactivation that can occur with AI monotherapy.